PersonalisPSNL +11.13%59 Days Payable is 77.08 as of Mar. 2026, which is 14% above its 10-year median of 67.32. GuruFocus rates PSNL with a GF Score™ of 59/100 and a GF Value™ of $2.07 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Personalis ranks better than 51.83% on this metric.
Personalis's average Accounts Payable for the
three
months ended in Mar. 2026 was $12.83 Mil. Personalis's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $15.19 Mil.
Hence, Personalis's Days Payable for the
three
months ended in Mar. 2026 was 77.08.
The historical rank and industry rank for Personalis's Days Payable or its related term are showing as below:
PSNL'
s Days Payable Range Over the Past 10 Years
Min: 48.76 Med: 67.32 Max: 125.49
Current: 71.67
During the past 9 years, Personalis's highest Days Payable was 125.49. The lowest was 48.76. And the median was 67.32.
PSNL's Days Payable is ranked better than 51.83% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs PSNL: 71.67
Personalis's Days Payable
increased
from Mar. 2025 (48.73) to Mar. 2026 (77.08).
It may suggest that Personalisdelayed paying its suppliers.
Personalis Days Payable Related Terms
Personalis Days Payable Historical Data
* Premium members only.
The historical data trend for Personalis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Personalis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Personalis Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's Days Payable distribution charts can be found below:
* The bar in red indicates where Personalis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Personalis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Personalis (PSNL) has a Days Payable of 77.08 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Personalis and its competitors. This is 14% above median its historical median of 67.32. Over the past decade, Personalis' Days Payable has ranged from 48.76 to 125.49. According to the industry distribution chart, Personalis ranks #92 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 48.2%.
Is Personalis' Days Payable too high?
Personalis' current Days Payable of 77.08 is 14% above median its 10-year median of 67.32. Over the past 10 years, this metric has ranged from a low of 48.76 to a high of 125.49. The Medical Diagnostics & Research industry median Days Payable is 68.87. Personalis' value of 77.08 is 11.9% above this industry median. Based on the distribution chart, Personalis ranks #92 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Personalis has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Personalis' Days Payable compare to CDNA and OPK?
According to the Medical Diagnostics & Research industry distribution chart, Personalis ranks #92 out of 191 companies for Days Payable. This puts Personalis in the upper half of its industry. The industry median Days Payable is 68.87. Personalis' value of 77.08 is 11.9% above this benchmark. Historically, Personalis' own Days Payable has ranged from 48.76 to 125.49 over the past decade. While the company's 10-year median is 67.32 vs. the industry median of 68.87, Personalis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Personalis's current Days Payable of 77.08 is 11.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Personalis and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Personalis's current Days Payable is 77.08, which is 14% above median its own 10-year median of 67.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Personalis stock overvalued right now?
Based on GuruFocus' analysis, Personalis (PSNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.07, compared to a current price of $11.18 — trading 440.1% above its estimated fair value. The current Days Payable is 77.08, which is 14% above median its 10-year median of 67.32 and 11.9% above the Medical Diagnostics & Research industry median of 68.87. Personalis' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Personalis (PSNL), the current Days Payable is 77.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Personalis (PSNL) Overvalued in 2026?
Based on GuruFocus' analysis, Personalis stock appears to be overvalued.
The current stock price of $11.18 is trading 440.1% above its estimated GF Value™ of $2.07.
GuruFocus considers Personalis to be Significantly Overvalued.
Key valuation signals for PSNL:
Days Payable: 77.08 (14% above median its 10-year median of 67.32)
GF Value™: $2.07 vs. price of $11.18 (440.1% above fair value)
Industry Position: 11.9% above the Medical Diagnostics & Research median (#92 of 191)
No single metric tells the full story. See the PSNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
59GF Score
Get the complete analysis for PSNL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSNL has been successfully added to your 
